Keravision Inc/DE – ‘8-K’ for 7/1/99 – EX-99.24

On:  Thursday, 7/1/99   ·   For:  7/1/99   ·   Accession #:  946154-99-20   ·   File #:  0-26316

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      9K 
 2: EX-99.23    News Release Dated 6/21/1999                           3±    12K 
 3: EX-99.24    News Release Dated 6/26/1999                           2±    11K 

EX-99.24   —   News Release Dated 6/26/1999

EX-99.24
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
                                                               Exhibit 99.24
FOR IMMEDIATE RELEASE                             Saturday, June 26th, 1999     

INTAC PROVE EFFECTIVE AS TREATMENT FOR NEARSIGHTEDNESS FOR FIRST GROUP          
OF CANADIAN PATIENTS                                                            

15 Minute Procedure is Option to Eyeglasses, Contacts, and Laser Surgery        

Halifax, NS - Seven in 10 Canadians who were treated with Intacs - the          
first HPB-approved non-laser option for surgically correcting myopia            
(nearsightedness) - can now see with 20/20 vision, according to clinical        
results announced at the 1999 Canadian Ophthalmology Society (COS) and          
Canadian Society of Cataract and Refractive Surgeons Conference (CSCRS)         
in Halifax today.                                                               

A total of 94 per cent of Intacs patients saw 20/40 or better - the             
standard for driving a car in Canada.  The results were based on the            
experiences of 51 Intacs patients who were among the first to receive           
the pioneering treatment following HPB approval in May 1998.  The data          
were collected from seven different clinical sites across Canada as part        
of the routine follow up care.  There were no incidences of infection.          

"Canadian patients are achieving excellent results that are very much           
in-line with results from the eight-year FDA study that preceded HPB            
approval.  Our patients are experiencing significantly better vision            
within one day of treatment," said former CSCRS president, David                
Edmison, M.D., of the Focus Eye Centre in Ottawa, who presented these           
results at the conference.                                                      

The Intacs treatment is presently available at 23 vision correction             
surgery centers across Canada from 37 ophthalmic surgeons.                      
Approximately 6.5 million nearsighted Canadians are within the approved         
treatment range of -1.0 to -5.0 diopters and could potentially benefit          
from Intacs.                                                                    

Intacs, unlike laser treatments, reshape the cornea's curvature and             
correct vision by adding a clear ultra-thin polymer to the eye, instead         
of by cutting or removing tissue.  While intended to permanently correct        
nearsightedness, Intacs are also removable and designed to be reversible        
in their refractive effect.  Patients thus have the freedom of having           
their correction changed if their vision needs change with age.  US             
clinical studies found that 100 per cent of patients returned to within         
one diopter of their original refraction after their Intacs were removed        
and 86 per cent returned to within one-half diopter.                            

Findings also show quality of vision better than PRK or LASIK.  In a            
comparative study with LASIK at the Hunkeler Vision Center in Kansas            
City, Intacs outperformed the LASIK technique when used to treat mild           
nearsightedness.                                                                

"Intacs are clearly a superior product and outperform other vision              
correction options such as LASIK or PRK to treat mild nearsightedness, "        
Dr. Edmison stated.                                                             

"Consumers who have been hesitant to get their vision corrected through         
laser eye surgery may find Intacs an attractive option because of their         
removability and the peace of mind that goes with it," Dr. Edmison              
added.                                                                          

The Intacs treatment takes about 15 minutes and is performed in an              
outpatient setting and usually with a topical eyedrop anesthetic.               
Intacs' polymer material has been surgically used in eyes for nearly 50         
years.                                                                          

KeraVision, Inc. of Fremont, California, is the developer of the first          
FDA-approved non-laser option for the surgical treatment of mild to             
moderate myopia (nearsightedness).  Intacs are a safe and convenient            
alternative to eyeglasses, contact lenses and vision correction                 
surgeries that permanently alter the eye's central optical zone.  The           
initial product is KeraVision Intacs for myopia, developed from a               
technology platform that the company believes will potentially treat the        
most common forms of vision problems.  KeraVision Inc. is traded on             
Nasdaq (KERA).                                                                  

Except for the historical information, the matters discussed in this            
news release are forward-looking statements.  Actual results may differ         
materially due to a variety of factors, including market acceptance of          
KeraVision Intacs, complications relating to the product or the surgical        
procedure, competitive products and the technologies, and other risk            
factors described under the heading, "Risk Factors Affecting the                
Company, Its Business and Its Stock Price" set forth in Form 10-Q for           
the quarter ended March 31, 1999, and form 10-K for the year ended              
December 31, 1998, as well as in other SEC filings.                             

Note to Editors:  KeraVision and Intacs are registered trademarks or            
trademarks of KeraVision, Inc., in the U.S. and foreign countries.              

-30-                            
For more information, please call:                                              

Colleen Savage, GPC Communications - Toronto                                    
(416) 598-0055 ext. 245                                                         

Judy Morrison, GPC Communications - Ottawa                                      
(613) 238-2747 ext. 335                                                         

Lori Pike, GPC Communications - Vancouver                                       
(604) 688-2505 ext. 223                                                         

Isabelle Baccichet, GPC Concordia - Montreal                                    
(514) 282-1100 ext. 110                                                         

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing		Date		Other Filings
Filed on / For Period End:		7/1/99
		3/31/99		10-K,  10-Q
		12/31/98		10-K,  10-K/A
				List all Filings